[ad_1]
European Commissioner for the Internal Market, Thierry Breton, believes that the European Union can ensure that the continent’s residents receive immunity against the coronavirus without using the Russian Sputnik V vaccine.
The European Union does not need the Russian Sputnik V vaccine against COVID-19. This was announced on March 21 by Internal Market Commissioner Thierry Breton, who heads the EU working group on vaccines, Reuters says.
According to him, the European Union “absolutely does not need Sputnik V.” Breton emphasized that today the EU has the opportunity to receive 300 to 350 million doses of European vaccines by the end of June, and by July 14, to achieve immunity. across the continent.
Russian vaccine developers on Twitter accused The Breton bias.
“Commissioner Thierry Breton is clearly inclined towards the Sputnik V vaccine just because he is Russian. He ignores the fact that this vaccine is more effective and safer than some other vaccines approved in the EU,” the message reads.
Notary @ThierryBreton it is clearly biased against the Sputnik V vaccine just because it is Russian. It ignores that it has higher efficacy and a better safety record than some other vaccines approved in the EU.
– Sputnik V (@sputnikvaccine) March 21, 2021
The European Medicines Agency (EMA) urged EU countries not to rush to approve the Sputnik V vaccine. In an interview with Austrian TV channel ORF, EMA board director Christa Virtumer-Hohe, said that the controls of the Russian drug agency had not yet been completed and that there was insufficient data to approve the Sputnik V vaccine. In material from the France 24 television channel, Virtumer-Hohe compared the idea of an emergency approval of Russian COVID-19 drug with “Russian roulette”.
The Sputnik V vaccine was registered in Russia on August 11 last year. Russian President Vladimir Putin argued that it is effective, forms a stable immunity and has passed all tests.
The vaccine has received criticism in the scientific community, since it was registered before the third phase of clinical trials. In Russia, they claimed to be 95 percent effective. The international journal The Lancet wrote an efficiency of 91.6%.
At the same time, several Russian scientists pointed out that the accelerated approach to vaccine registration is contrary to scientific and ethical standards for drug development. The vaccinated Russians complained of various side effects: fever, loss of smell, high blood pressure.
The Sputnik V vaccine has not been approved in the European Union. In Russia, mass vaccination with a national drug is being carried out. According to Russia’s Direct Investment Fund, on March 19, the Sputnik V vaccine was approved for use in 54 countries.
The head of the European Commission, Ursula von der Leyen, during a speech in Brussels on February 17, expressed surprise that Russia is offering Sputnik V to other countries without vaccinating its own population.
[ad_2]
